Nexus and Nevakar face off over hypotension drug

Nexus Pharmaceuticals and rival Nevakar have gone to court to determine which company has the right to sell a new hypotension drug, which can be administered to patients under anesthesia during surgery.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Big Pharma

Pharma company raises pressure with hypotension drug lawsuit

13 October 2022 Nexus raises second complaint against same parties in a month | Ready-to-use drug that can raise the blood pressure of hypotension patients at issue.

Americas

FDA approves milestone biosimilar insulin drug

29 July 2021 The US Food and Drug Administration has approved the first-ever interchangeable biosimilar product, an insulin treatment for Types 1 and 2 diabetes.

Americas

Medicure and Nexus agree Aggrastat generic licence

20 November 2020 US cardiovascular therapies company Medicure has settled a patent infringement dispute with rival Nexus Pharmaceuticals.

More on this story

Big Pharma

Pharma company raises pressure with hypotension drug lawsuit

13 October 2022 Nexus raises second complaint against same parties in a month | Ready-to-use drug that can raise the blood pressure of hypotension patients at issue.

Americas

FDA approves milestone biosimilar insulin drug

29 July 2021 The US Food and Drug Administration has approved the first-ever interchangeable biosimilar product, an insulin treatment for Types 1 and 2 diabetes.

Americas

Medicure and Nexus agree Aggrastat generic licence

20 November 2020 US cardiovascular therapies company Medicure has settled a patent infringement dispute with rival Nexus Pharmaceuticals.

More on this story

Big Pharma

Pharma company raises pressure with hypotension drug lawsuit

13 October 2022 Nexus raises second complaint against same parties in a month | Ready-to-use drug that can raise the blood pressure of hypotension patients at issue.

Americas

FDA approves milestone biosimilar insulin drug

29 July 2021 The US Food and Drug Administration has approved the first-ever interchangeable biosimilar product, an insulin treatment for Types 1 and 2 diabetes.

Americas

Medicure and Nexus agree Aggrastat generic licence

20 November 2020 US cardiovascular therapies company Medicure has settled a patent infringement dispute with rival Nexus Pharmaceuticals.